ArticleFrontiers in neuroscience2026
STAT3 signaling is associated with neuroimmune dysregulation in a Dravet syndrome model and pediatric drug-resistant epilepsy.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy, mainly caused by Methods: We conducted a multi-level integrative analysis combining transcriptomic mining of the GEO database to identify the Results: Transcriptomic profiling of Conclusion: This study identifies systemic and neuroinflammatory changes in DS associated with increased STAT3 signaling and this inflammatory signature is also observed in the broader pediatric DRE population. By bridging verified molecular mechanisms with real-world clinical data from our pediatric cohort, we suggest peripheral indices (NLR, SII, CRP) that may serve as accessible clinical indicators of disease severity in pediatric DRE. Pending functional validation, these findings identify STAT3 as a pathway of interest and a potential therapeutic candidate, supporting the development of adjunctive anti-inflammatory therapies targeting neuroimmune cascades for DS and broader refractory epilepsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.